Hyderabad:At a time when most countries of the world witness an increase in the number of COVID-19 positive cases, the risk of running low on several essential drugs poses a grave challenge to the fight against the deadly virus, particularly in countries such as the United States, which has emerged as the new epicentre of the disease.
Several media reports suggest an acute shortage of critical medicines, particularly sedatory drugs including albuterol neuromuscular blockers sedatives such as fentanyl, midazolam, and propofol; and vasopressors for septic shock, in the face of increasing demand.
“The rates at which hospitals traditionally had been able to fill orders for ventilator-associated drugs was 95%, which has dropped to 60 or 70% in the last month alone,” Medscape Medical News quoted Dan Kistner, senior vice president for pharmacy solutions at Vizient, a group purchasing organization that negotiates medicine contracts for about 3000 hospitals and healthcare facilities in the US.
The severity of the situation can be gauged from a tweet posted by Esther Choo, MD, MPH, an emergency physician at Oregon Health & Science University in Portland, who recently tweeted, “Those ventilators can’t really be used without a similarly vast supply of coupled medications to get people *on* the vents — and keep them on humanely. Hospitals are already experiencing shortages, before we even hit disease apex.”
A recently released report by Premier, a healthcare improvement company based in Charlotte, North Carolina, pointed out that 15 drugs used for COVID-19 care are in shortage or close to being in short supply, particularly in New York.
Also read:India faces greatest economic emergency since Independence: Raghuram Rajan
The report suggests that while orders for Albuterol - a sedatory drug, increased this month by 1870%, its supply couldn’t match the demand. Similarly, orders for fentanyl doubled nationally in March and were up 533% in New York for the month. Only 61% of orders are now being filled, Premier reports.